BACKGROUND There is no widely accepted standard medical treatment for apocrine gland anal sac adenocarcinoma (AGASACA) in dogs. Targeted agents such as toceranib may be effective in treatment of AGASACA, but the number of clinical reports investigating its efficacy is limited. HYPOTHESIS/AIM To evaluate the efficacy of toceranib treatment of AGASACA in dogs, and to assess prognostic factors in the study population. Our hypothesis was that toceranib would provide a clinical benefit in the treatment of dogs with AGASACA. ANIMALS Thirty-six client-owned dogs with either a cytologic or histologic diagnosis of AGASACA that were treated with toceranib alone or in combination with surgery, nonconcurrent chemotherapy or both. METHODS Retrospective study. RESULT The median progression-free survival (PFS) and overall survival time (OST) for the study population was 313 days and 827 days, respectively. A clinical benefit from toceranib treatment was observed in 69% of dogs, with 20.7% of dogs experiencing partial response and 48.3% of dogs experiencing stable disease. Dogs that responded to toceranib treatment had significantly prolonged PFS and OST. Hypercalcemia was a negative prognostic factor for clinical outcomes. CONCLUSIONS Toceranib is effective in the treatment of AGASACA in dogs. Prospective, controlled clinical trials are needed to determine the efficacy of toceranib in comparison to other treatment protocols for dogs with AGASACA.

中文翻译：

---

托塞尼布治疗犬大汗腺肛门囊腺癌的评价。

背景 对于狗的大汗腺肛门囊腺癌 (AGASACA)，尚无广泛接受的标准药物治疗。靶向药物如 toceranib 可能对 AGASACA 的治疗有效，但研究其疗效的临床报告数量有限。假设/目的 评估托塞尼布治疗犬 AGASACA 的疗效，并评估研究人群的预后因素。我们的假设是，toceranib 会为患有 AGASACA 的犬提供临床益处。动物 36 只客户拥有的狗，其细胞学或组织学诊断为 AGASACA，单独使用托塞尼布或与手术、非同步化疗或两者联合治疗。方法回顾性研究。结果 研究人群的中位无进展生存期 (PFS) 和总生存期 (OST) 分别为 313 天和 827 天。在 69% 的狗中观察到托塞尼布治疗的临床益处，其中 20.7% 的狗出现部分反应，48.3% 的狗出现疾病稳定。对托塞尼布治疗有反应的狗显着延长了 PFS 和 OST。高钙血症是临床结果的负面预后因素。结论 Toceranib 可有效治疗狗的 AGASACA。需要进行前瞻性对照临床试验来确定托塞尼布与其他 AGASACA 犬治疗方案相比的疗效。7% 的狗经历部分反应，48.3% 的狗经历稳定的疾病。对托塞尼布治疗有反应的狗显着延长了 PFS 和 OST。高钙血症是临床结果的负面预后因素。结论 Toceranib 可有效治疗狗的 AGASACA。需要进行前瞻性对照临床试验来确定托塞尼布与其他 AGASACA 犬治疗方案相比的疗效。7% 的狗经历部分反应，48.3% 的狗经历稳定的疾病。对托塞尼布治疗有反应的狗显着延长了 PFS 和 OST。高钙血症是临床结果的负面预后因素。结论 Toceranib 可有效治疗狗的 AGASACA。需要进行前瞻性对照临床试验来确定托塞尼布与其他 AGASACA 犬治疗方案相比的疗效。